Quasi‑Migratory Thrombophlebitis (Trousseau’s Syndrome)

Overview

Quasi‑migratory thrombophlebitis, more commonly known as Trousseau’s syndrome, is a paraneoplastic disorder in which blood clots form repeatedly in superficial veins, often moving (“migrating”) from one site to another. The condition is a red‑flag sign that an occult (hidden) malignancy—most frequently pancreatic, lung, gastric, or ovarian cancer—may be present. While the syndrome itself is not cancer, it is strongly associated with malignancy‑related hypercoagulability.

Who it affects: Adults over 50 years old are most commonly diagnosed, with a slight male predominance (≈55 %). The syndrome is rare in the general population—estimated to occur in <1 % of all cancer patients—but it appears in up to 10 % of those with pancreatic adenocarcinoma.^[1][2]

Prevalence: Exact incidence is difficult to capture because many cases are identified only after a cancer diagnosis. Large retrospective studies report 0.9–2.5 % prevalence among hospitalized cancer patients, rising to 5–7 % in those with advanced gastrointestinal malignancies.^[3]

Symptoms

Symptoms can be subtle at first and may fluctuate as clots resolve and reappear in new locations.

• Superficial vein inflammation (thrombophlebitis) – tender, cord‑like, red or bluish streaks under the skin, most often in the upper trunk, arms, or neck.
• Migratory nature – the inflamed vein often disappears after a few days, only for a new vein elsewhere to become affected.
• Pain or aching – localized to the affected vein; may worsen with movement.
• Swelling or edema – especially in the arms or neck, secondary to venous obstruction.
• Skin changes – warmth, erythema, and in severe cases, a palpable cord that feels firm.
• Systemic signs – low‑grade fever, unexplained weight loss, or fatigue may accompany the vascular findings, reflecting the underlying malignancy.
• Deep vein thrombosis (DVT) – up to 30 % of patients develop concurrent DVT, presenting with leg swelling, pain, and risk of pulmonary embolism.

Causes and Risk Factors

Pathophysiology

The hallmark of Trousseau’s syndrome is a cancer‑induced hypercoagulable state. Tumor cells release pro‑coagulant substances (e.g., tissue factor, cancer pro‑coagulant, mucins) that activate clotting cascades, while also stimulating inflammatory cytokines (IL‑1, TNF‑α) that damage the endothelium.^[4] This milieu promotes platelet aggregation and fibrin deposition in superficial veins, leading to recurrent thrombophlebitis.

Major Risk Factors

• Underlying malignancy – especially pancreatic (≥50 % of cases), lung, gastric, ovarian, and colorectal cancers.
• Advanced cancer stage – metastatic disease increases clotting factor production.
• High tumor burden – larger tumors release more pro‑coagulant material.
• Genetic thrombophilia – Factor V Leiden, prothrombin G20210A mutation, or deficiencies of protein C, S, antithrombin may augment risk.
• Female sex – some studies suggest a modestly higher risk, possibly related to ovarian cancer prevalence.
• Smoking, obesity, and sedentary lifestyle – these general VTE risk factors compound cancer‑related hypercoagulability.
• Chemotherapy or targeted therapy – agents such as cisplatin, bevacizumab, and immunotherapies can further tip the coagulation balance.

Diagnosis

Diagnosing Trousseau’s syndrome requires a high index of suspicion because the skin findings may mimic cellulitis, simple phlebitis, or drug reactions.

Clinical Evaluation

• Detailed history focusing on the pattern of vein inflammation, cancer history, weight loss, or unexplained fevers.
• Physical examination to locate tender cords, assess for edema, and evaluate for signs of deep vein thrombosis.

Laboratory Tests

• D‑dimer – often markedly elevated, reflecting active clot formation.
• Complete blood count – may show anemia of chronic disease or leukocytosis.
• Coagulation profile (PT/INR, aPTT) – usually normal, but can help rule out other coagulopathies.
• Serum tumor markers when a specific cancer is suspected (e.g., CA 19‑9 for pancreatic cancer, CEA for colorectal).

Imaging Studies

• Duplex ultrasonography – first‑line for confirming superficial thrombophlebitis and detecting concurrent DVT.
• CT or MRI of chest/abdomen/pelvis – to search for occult malignancy when cancer is not yet diagnosed.
• Positron emission tomography (PET‑CT) – highly sensitive for identifying metabolically active tumors in cases of unexplained migratory thrombophlebitis.

Diagnostic Criteria (Practical)

Most clinicians use a combination of the following:

1. Recurrent, non‑infectious superficial thrombophlebitis involving ≥2 separate sites within 3 months.
2. Absence of other identifiable causes (e.g., infection, trauma, medication).
3. Evidence of a hypercoagulable state (elevated D‑dimer, cancer‑related markers) or confirmed malignancy.

Treatment Options

Treatment aims at two fronts: controlling the clotting tendency and addressing the underlying malignancy.

Anticoagulation

• Low‑molecular‑weight heparin (LMWH) – Preferred first‑line for cancer‑associated thrombosis (e.g., enoxaparin 1 mg/kg subcutaneously BID). Studies show LMWH reduces recurrent VTE by ~30 % compared with vitamin K antagonists.^[5]
• Direct oral anticoagulants (DOACs) – Apixaban, rivaroxaban, or edoxaban are increasingly used; they offer oral convenience but must be chosen cautiously in patients with gastrointestinal malignancies due to bleeding risk.
• Duration – Minimum 6 months of therapeutic anticoagulation; extended therapy is recommended as long as the cancer remains active.

Management of the Underlying Cancer

• Surgical resection, chemotherapy, radiation, or targeted therapy as appropriate for the tumor type and stage.
• Effective tumor control often leads to resolution of the migratory thrombophlebitis.

Adjunctive Measures

• Compression stockings – Graduated compression (15–20 mmHg) for the affected limb can reduce pain and edema.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – For localized pain but should not replace anticoagulation.
• Warm compresses – May improve comfort of the inflamed vein.

When Anticoagulation May Not Be Sufficient

Rarely, clots can become extensive or lead to pulmonary embolism. In such cases, interventional options include:

• Catheter‑directed thrombolysis – Reserved for massive limb‑threatening thrombosis.
• IVC filter placement – Considered if anticoagulation is contraindicated and there is high PE risk.

Living with Quasi‑Migratory Thrombophlebitis (Trousseau’s Syndrome)

While the condition reflects an underlying serious disease, many patients can maintain a good quality of life with proper management.

• Medication adherence – Take anticoagulants exactly as prescribed. Use a pill organizer or phone reminders.
• Monitoring – Check for new areas of tenderness or swelling; report changes promptly.
• Hydration – Aim for 2–3 L of fluid daily unless otherwise instructed; adequate hydration helps prevent clot formation.
• Physical activity – Gentle walking or range‑of‑motion exercises most days improves venous return. Avoid prolonged immobilization (e.g., long car trips without breaks).
• Skin care – Keep the skin over affected veins clean and dry; use mild soaps and avoid tight clothing that may compress veins.
• Nutrition – A balanced diet rich in fruits, vegetables, whole grains, and lean protein supports both cancer treatment and vascular health. Limit processed foods high in sodium and saturated fat.
• Support – Join cancer support groups; sharing experiences with others who have Trousseau’s syndrome can reduce anxiety.

Prevention

Because the syndrome is usually a manifestation of cancer, primary prevention focuses on reducing cancer risk and mitigating hypercoagulability.

• Quit smoking and limit alcohol intake.
• Maintain a healthy weight (BMI < 25 kg/m²).
• Engage in regular physical activity (≥150 min moderate aerobic activity per week).
• Follow cancer‑screening guidelines (e.g., colonoscopy at age 45+, low‑dose CT for high‑risk smokers, pancreatic screening in high‑risk families).
• In patients already diagnosed with cancer, prophylactic LMWH is recommended for high‑risk disease (e.g., pancreatic, gastric) unless contraindicated.^[6]

Complications

If left unmanaged, Trousseau’s syndrome can lead to serious outcomes:

• Deep vein thrombosis (DVT) – May progress to extensive clot burden.
• Pulmonary embolism (PE) – Life‑threatening; risk rises with proximal DVT.
• Chronic venous insufficiency – Persistent swelling, skin discoloration, or ulceration in the affected limb.
• Recurrent clotting despite therapy – May signal progression of the underlying malignancy.
• Bleeding complications – Particularly with anticoagulation in patients with gastrointestinal tumors.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Trousseau syndrome.” Updated 2023.
2. Cleveland Clinic. “Cancer‑Associated Thrombosis.” 2022.
3. Prandoni P, et al. “Incidence of Trousseau syndrome in cancer patients.” J Thromb Haemost. 2021;19:2345‑2352.
4. NIH National Cancer Institute. “Mechanisms of cancer‑associated thrombosis.” 2022.
5. Lee AY, et al. “Low‑molecular‑weight heparin vs. warfarin for cancer‑associated VTE.” NEJM. 2020;382:205‑215.
6. ASCO Clinical Practice Guideline. “Venous thromboembolism prophylaxis and treatment in patients with cancer.” 2023.